Biocon is currently trading at Rs. 414.30, up by 0.25 points or 0.06% from its previous closing of Rs. 414.05 on the BSE.

The scrip opened at Rs. 416.00 and has touched a high and low of Rs. 416.00 and Rs. 412.30 respectively. So far 14293 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 440.30 on 26-May-2026 and a 52 week low of Rs. 331.00 on 11-Aug-2025.

Last one week high and low of the scrip stood at Rs. 440.30 and Rs. 348.05 respectively. The current market cap of the company is Rs. 67259.57 crore.

The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 31.59% and 23.49% respectively.

Biocon has acquired an equity stake in Ampin C&I Power Twelve (AMPIN), a Special Purpose Vehicle (SPV) formed for the generation and supply of solar power, by investing around Rs 5.47 crore towards the subscription of 54.76 lakh equity shares.

To enhance the renewable based power consumption, Biocon has acquired and will maintain equity stake in AMPIN throughout the terms of the Power Purchase Agreement and Share Purchase, Subscription and Shareholders Agreement (Agreements) entered between the Company and AMPIN to maintain captive status as per Electricity Act. This acquisition aligns with the company’s renewable energy objectives, supporting the procurement of green energy and advancing its decarbonization goals and will help the company in reducing its energy cost and carbon footprint.

With the above investment, the company will hold 59.76 lakh Equity shares of AMPIN representing 37.77% of its paid-up share capital (on an undiluted basis) as on date. However, post the proposed investment by other entities in AMPIN, the aforesaid percentage of investment of the Company will stand reduced to 15.91% of the paid-up share capital of AMPIN (on a fully diluted basis) as per the terms of the Agreements entered by the Company.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Ltd.